Investing.com - BioLineRx reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
BioLineRx announced earnings per share of $-0.1493 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.1667 on revenue of $0.00.
BioLineRx shares are up 9.92% from the beginning of the year, still down 56.31% from its 52 week high of $6.34 set on May 4. They are under-performing the Nasdaq which is up 13.75% from the start of the year.
BioLineRx shares lost 4.15% in intra-day trade following the report.
BioLineRx follows other major Healthcare sector earnings this month
BioLineRx's report follows an earnings beat by Abbott Labs on July 22, who reported EPS of $1.17 on revenue of $10.22B, compared to forecasts EPS of $1.02 on revenue of $9.69B.
Merck ADR had beat expectations on August 5 with second quarter EPS of $0.5304 on revenue of $5.77B, compared to forecast for EPS of $0.4897 on revenue of $5.63B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar